'מערכת אימד'Roblin X et.al.; J Crohns Colitis. 2023 Nov 2:jjad188
Abstract
Background: The relationship between SC-IFX concentrations and favorable therapeutic outcomes in patients with Crohn's disease (CD) and ulcerative colitis (UC) remain elusive.
Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S, Cheifetz A, Fabien N, Barrau M, Paul S. Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. J Crohns Colitis. 2023 Nov 2:jjad188. doi: 10.1093/ecco-jcc/jjad188. Epub ahead of print. PMID: 37934041.